United Kingdom

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

12 Dec 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant... (more)


Beta: 2.03
Market Cap(Mil.): $187.67
Shares Outstanding(Mil.): 41.07
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Advaxis Q4 loss per share $1.74

* Advaxis reports business update and third quarter 2017 results

11 Sep 2017

Advaxis CEO Daniel O'Connor resigns

July 6 Cancer immunotherapy developer Advaxis Inc said on Thursday Daniel O'Connor stepped down from his position as the company's chief executive and its board.

06 Jul 2017

BRIEF-Advaxis names ‍Anthony Lombardo interim CEO

* Advaxis inc - ‍Anthony Lombardo named interim chief executive officer​

06 Jul 2017

BRIEF-Advaxis says confirms is on track to initiate clinical studies of ADXS-NEO later this year

* Company confirmed that it is on track to initiate clinical studies of ADXS-NEO later this year

13 Jun 2017

Earnings vs. Estimates